Breast Cancer Clinical Trial

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Summary

The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer
Disease progression following non-steroidal aromatase inhibitor treatment

Exclusion Criteria:

Known symptomatic brain metastasis
Medical condition requiring chronic steroids
History of Type 1 or 2 Diabetes
Uncontrolled or significant cardiovascular (CV) disease
Concomitant second malignancies

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

77

Study ID:

NCT01225172

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

Univ Of Al At Birmingham
Birmingham Alabama, 35294, United States
Mayo Clinic Arizona
Scottsdale Arizona, 85259, United States
Sharp Clinical Oncology Research
San Diego California, 92123, United States
Mayo Clinic
Jacksonville Florida, 32224, United States
University Of Chicago Medical Center
Chicago Illinois, 60637, United States
Illinois Cancercare, Pc
Peoria Illinois, 61615, United States
Indiana University Health Goshen Center For Cancer Care
Goshen Indiana, 46526, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore Maryland, 21231, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore Maryland, 21231, United States
Oncology Care Associates, P.A.
Wheaton Maryland, 20902, United States
Masonic Cancer Ctr, University Of Minnesota
Minneapolis Minnesota, 55455, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Unv. Of Nc At Chapel Hill
Chapel Hill North Carolina, 27599, United States
Unv. Of Nc At Chapel Hill
Chapel Hill North Carolina, 27599, United States
Presbyterian Hospital Cancer Research
Charlotte North Carolina, 28204, United States
Duke University Medical Center-Dept Of Medicine
Durham North Carolina, 27710, United States
Ut Md Anderson Can Ctr.
Houston Texas, 77030, United States
Ut Md Anderson Can Ctr.
Houston Texas, 77030, United States
University Of Virginia Health System
Charlottesville Virginia, 22908, United States
University Of Wisconsin
Madison Wisconsin, 53792, United States
University Of Wisconsin
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

77

Study ID:

NCT01225172

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider